Abstract
Busulfan/fludarabine (BuFlu) is a widely used conditioning regimen for patients with myeloid malignancies. The sequential FLAMSA (fludarabine + Ara-C + amsacrine chemotherapy) protocol followed by either cyclophosphamide and total body irradiation (FLAMSA-TBI) or cyclophosphamide and busulfan (FLAMSA-Bu) has shown remarkable activity in high-risk acute myelogenous leukemia (AML) patients. Here we compare the outcomes of AML patients transplanted in first complete remission (CR1) or second complete remission (CR2) after conditioning with BuFlu or FLAMSA. Eligible patients had their first allogeneic stem cell transplantation for AML in CR1 or CR2 between January 2005 and June 2016. Donors were matched related or unrelated with up to 1 mismatch. Conditioning consisted of either BuFlu or FLAMSA. Propensity score matching was applied and comparisons were performed using weighted Cox regression. BuFlu conditioning was used in 1197 patients, whereas FLAMSA-TBI and FLAMSA-Bu were used in 258 and 141 patients, respectively. Median follow-up of survivors was 24.72 months. In univariate analysis, relapse incidence (RI) was 30.3%, 21.9%, and 23.1% in the BuFlu, FLAMSA-TBI, and FLAMSA-Bu groups, respectively (P < .01), and nonrelapse mortal...Continue Reading
References
Oct 1, 1974·Transplantation·H GlucksbergE D Thomas
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph SchmidHans-Jochem Kolb
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Jan 8, 2008·Bone Marrow Transplantation·C SchmidH-J Kolb
Apr 14, 2010·Blood·David GrimwadeUNKNOWN National Cancer Research Institute Adult Leukaemia Working Group
Mar 2, 2011·Bone Marrow Transplantation·C SchmidH-J Kolb
Sep 3, 2011·European Journal of Haematology·Stefanie BuchholzArnold Ganser
Aug 16, 2012·Cancer·Didier BlaiseMauricette Michallet
Mar 20, 2013·Statistics in Medicine·Daniel F McCaffreyLane F Burgette
Apr 9, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yi-Bin ChenVincent T Ho
Jul 1, 2014·Bone Marrow Transplantation·M A Kharfan-DabajaM Mohty
Nov 27, 2014·Cancer·Frédéric BaronMohamad Mohty
May 25, 2015·Leukemia Research·Mohamed A Kharfan-DabajaMohamad Mohty
Jul 2, 2015·Haematologica·Salyka SengsayadethMohamad Mohty
Oct 3, 2015·The Lancet Oncology·Alessandro RambaldiAlberto Bosi
Dec 15, 2015·Bone Marrow Transplantation·A RuggeriA Nagler
Aug 27, 2016·Haematologica·Mohamad MohtyPatrice Chevallier
Nov 7, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Florent MalardArnon Nagler
Nov 24, 2016·British Journal of Haematology·Olle RingdénUNKNOWN Acute Leukaemia Working Party of the EBMT
Nov 30, 2016·Blood·Hartmut DöhnerClara D Bloomfield
Dec 3, 2016·Annals of Hematology·Udo HoltickJens M Chemnitz
Apr 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bart L ScottMitchell E Horwitz
Nov 2, 2017·Annals of Hematology·Gabriele NagelUNKNOWN German-Austrian AML Study Group (AMLSG)
Dec 17, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Avichai ShimoniArnon Nagler
Citations
Sep 19, 2018·International Journal of Molecular Sciences·Caroline A AustinIan G Cowell
Jul 1, 2020·Annals of Hematology·Hans-Jochem Kolb, Christoph Schmid
Sep 14, 2019·Journal of Clinical Medicine·Weerapat OwattanapanichFlorian Kuchenbauer
Oct 13, 2020·Leukemia & Lymphoma·Thomas HeinickeMohamad Mohty
Jul 28, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Eduardo Rodríguez-ArbolíMohamad Mohty
Feb 11, 2021·Medizinische Klinik, Intensivmedizin und Notfallmedizin·S-S StecherA Fraccaroli
Jul 20, 2020·Leukemia Research·Christopher R D'AngeloMark Juckett